TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01699334

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducational video
Description: The educational video will explain the nature of whiplash injuries and provide a biopsychosocial model for neck pain incorporating both physiological and cognitive-behavioural aspects, reassurance and basic advice on pain relief.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation video
Description: The comparison condition is a relaxation video detailing simple relaxation exercises such as breathing exercises which can be safely used by whiplash patients. The relaxation video contains no explanatory information concerning whiplash injuries or the related symptoms.
Study: NCT02622152

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Right lateral position (2 hours)
Description: Repositioning the patients for two-hours period on the right lateral position

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Right lateral position (2 hours)
Description: Repositioning the patients for two-hours period on the right lateral position

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Left lateral position (30 minutes)
Description: Repositioning the patients for 30 minutes period on the left lateral position

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Supine position (30 minutes)
Description: Repositioning the patients for 30 minutes period on the supine position

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Left lateral position (2 hours)
Description: Repositioning the patients for two-hours period on the left lateral position

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Supine position (2 hours)
Description: Repositioning the patients for two-hours period on supine position
Study: NCT03035565

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Training with Brain HQ
Description: Computerized Cognitive Training Brain HQ activities initiated and continued 1 hour/day, 5 days/week for 8 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computerized Crossword Puzzles
Description: Computerized Crossword Puzzles activities initiated and continued 1 hour/day, 5 days/week for 8 weeks
Study: NCT03154580

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: N-acetyl cysteine
Description: Participants will receive 4 capsules at 11:15am on each experimental session day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: N-acetyl cysteine
Description: Participants will receive 4 capsules at 11:15am on each experimental session day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetyl cysteine
Description: Participants will receive 4 capsules at 11:15am on each experimental session day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetyl cysteine
Description: Participants will receive 4 capsules at 11:15am on each experimental session day.
Study: NCT01464190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA21 (2.5 g tablet containing 500 mg iron)
Description: Dose range of 5.0 g/day (2 tablets/day) to 15.0 g/day (6 tablets/day).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevelamer carbonate
Description: Film coated, compressed tablets. Dose range of 2.4 g/day (3 tablets/day) to 14.4 g/day (18 tablets/day).
Study: NCT01896193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: Sofosbuvir (SOF) 400 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: Sofosbuvir (SOF) 400 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) tablets administered orally in a divided daily dose using weight-based dosing (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) tablets administered orally in a divided daily dose using weight-based dosing (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study: NCT04358016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terlipressin
Description: Evaluate the effect of Terlipression on the occurance of acute kidney injury in patients with upper-gastroentestinal bleeding

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Somatostatin
Description: Somatostatin
Study: NCT01328470

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel, cilostazol
Description: Patients with CKD received clopidogrel (75 mg/day)for 14 days Patients with CKD received clopidogrel (150 mg/day)for 14 days Patients with CKD received clopidogrel (75 mg/day)and cilostazol (100 mg twice daily)for 14 days 75mg clopidogrel in patients with normal kidney function for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel, cilostazol
Description: Patients with CKD received clopidogrel (75 mg/day)for 14 days Patients with CKD received clopidogrel (150 mg/day)for 14 days Patients with CKD received clopidogrel (75 mg/day)and cilostazol (100 mg twice daily)for 14 days 75mg clopidogrel in patients with normal kidney function for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel, cilostazol
Description: Patients with CKD received clopidogrel (75 mg/day)for 14 days Patients with CKD received clopidogrel (150 mg/day)for 14 days Patients with CKD received clopidogrel (75 mg/day)and cilostazol (100 mg twice daily)for 14 days 75mg clopidogrel in patients with normal kidney function for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel, cilostazol
Description: Patients with CKD received clopidogrel (75 mg/day)for 14 days Patients with CKD received clopidogrel (150 mg/day)for 14 days Patients with CKD received clopidogrel (75 mg/day)and cilostazol (100 mg twice daily)for 14 days 75mg clopidogrel in patients with normal kidney function for 14 days
Study: NCT01793038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitor (litrezole) plus uFSH arm
Description: literozole tablets 5 mg /day for days 3-7 plus intramuscular injections of uFSH 37.5 IU/day for days 3-12

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clomiphene citrate-uFSH arm
Description: clomiphene citrate 50 mg tablets twice /day for 5 days plus 37.5 IU uFSH IM injections daily for 10 days
Study: NCT03058354

Intervention type: DRUG
Intervention: Propofol
Description: Patient undergoing surgery at Queen Mary Hospital, Hong Kong between 2014 to 2016 using intraoperative TIVA with propofol.

Intervention type: PROCEDURE
Intervention: general anaesthesia
Description: Patient undergoing surgery at Queen Mary Hospital, Hong Kong between 2014 to 2016 using general anaesthesia methods other than intraoperative TIVA with propofol.
Study: NCT03075267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT010 (BGF MDI) 320/14.4/9.6 µg
Description: A single dose of study drug will be administered on Day 1 and BID doses will be administered Day 2 through Day 7 of the Treatment Period, with a final single administration of study drug occurring on the morning of Day 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT010 (BGF MDI) 160/14.4/9.6 µg
Description: A single dose of study drug will be administered on Day 1 and BID doses will be administered Day 2 through Day 7 of the Treatment Period, with a final single administration of study drug occurring on the morning of Day 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT003 (GFF MDI) 14.4/9.6 µg
Description: A single dose of study drug will be administered on Day 1 and BID doses will be administered Day 2 through Day 7 of the Treatment Period, with a final single administration of study drug occurring on the morning of Day 8.
Study: NCT00809445

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: On-site HIV rapid test and brief, prevention counseling
Description: Participants will be offered an on-site oral fluid HIV rapid test with brief prevention counseling that addresses both risk reduction and motivation to be HIV tested based on an evidence-based counseling approach.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: On- site HIV rapid test & information
Description: Participants will be offered an on-site oral fluid HIV rapid test with basic info.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Referral for off-site HIV testing
Description: Participants will be offered a referral list of HIV testing agencies in the community.
Study: NCT03874013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOD-4023
Description: MOD-4023 is a long-acting modified recombinant human growth hormone (r-hGH) which utilizes C-terminal peptide (CTP) technology. It will be provided as a solution for injection containing 20 or 50 mg/mL MOD-4023 in a multi-dose disposable pre-filled PEN.~MOD-4023 will be administered as a SC injection once weekly, using a delivery device.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Genotropin
Description: Genotropin® is dispensed in a 2-chamber cartridge. The front compartment contains recombinant somatropin, glycine, mannitol, sodium dihydrogen phosphate anhydrous and disodium phosphate anhydrous. The rear compartment contains m-Cresol and mannitol in water for injections.~A delivery device (Genotropin®) will be used for daily (evening/bedtime) SC administration of Genotropin® into the region of the upper arms, buttocks, thighs or abdomen (8 locations). Injection sites should be rotated.~Dose regimen for Genotropin®: 0.025 mg/kg/day (or 0.175 mg/kg/w divided equally to 7 injections over a week).
Study: NCT00818584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micafungin
Description: IV Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micafungin
Description: IV Administration
Study: NCT02377856

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegylated interferon alpha 2a, ribavirin
Description: pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
Study: NCT02490826

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Table-based T2T intervention
Description: Phonological therapy consists of a combination of phonological awareness activities, auditory and discrimination and auditory bombardment activities. This activities will be based on table top materials. The items used in the intervention will be based on the child's target speech production goals. This intervention will include the following areas:~* Auditory Bombardment;~* Auditory and discrimination;~* Letter-sound knowledge;~* Phoneme identity and phoneme matching;~* Blending;~* Segmentation;~* Rhyme;~* Phoneme manipulation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tablet-based T2T intervention
Description: Phonological therapy consists of a combination of phonological awareness activities, auditory and discrimination and auditory bombardment activities. This activities will be based on digital materials presented on a tablet. The items used in the intervention will be based on the child's target speech production goals. This intervention will include the following areas:~* Auditory Bombardment;~* Auditory and discrimination;~* Letter-sound knowledge;~* Phoneme identity and phoneme matching;~* Blending;~* Segmentation;~* Rhyme;~* Phoneme manipulation.
Study: NCT01096160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8226 BID, 1 mg
Description: MK-8266 1 mg administered as oral capsules (0.7 mg + 0.3 mg), BID for 10 consecutive days. Panel A was completed prior to initiation of Panel B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8266 BID, 1.8 mg
Description: MK-8266 1.8 mg administered as oral capsules (1 mg + 0.8 mg), BID for 10 consecutive days. Panel B was completed prior to initiation of Panel C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8266 TID, 1.8 mg
Description: MK-8266 1.8 mg administered as oral capsules (0.6 mg), TID for 10 consecutive days. Panel C was completed prior to initiation of Panel D.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8266 TID, 2.4 mg
Description: MK-8266 TID (Panel D), 2.4 mg administered as oral capsules (0.8 mg), TID for 10 consecutive days. Panel D was completed prior to initiation of Panel E.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8266 TID, 2.4 mg
Description: MK-8266 TID (Panel E), 2.4 mg administered as oral capsules (0.8 mg), TID for 10 consecutive days. Panel E was initiated after completion of Panel D.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo BID (Panel A)
Description: Placebo administered as oral capsules BID for 10 consecutive days. Panel A was completed prior to initiation of Panel B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo BID (Panel B)
Description: Placebo administered as oral capsules BID for 10 consecutive days. Panel B was completed prior to initiation of Panel C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo TID (Panel C)
Description: Placebo administered as oral capsules TID for 10 consecutive days. Panel C was completed prior to initiation of Panel D.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo TID (Panel D)
Description: Placebo administered as oral capsules TID for 10 consecutive days. Panel D was completed prior to initiation of Panel E.
Study: NCT03697304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 754111
Description: Solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 754111
Description: Solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836880
Description: Solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836880
Description: Solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836880
Description: Solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836880
Description: Solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836880
Description: Solution for infusion
Study: NCT01096160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo TID (Panel E)
Description: Placebo administered as oral capsules TID for 10 consecutive days. Panel E was initiated after completion of Panel D.
Study: NCT04085848

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music therapy
Description: 4 music therapy sessions during a period of time of 48 hours. Each session lasts 30 minutes.
Study: NCT01837251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLD

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study: NCT03768778

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Debridement and dural repair
Study: NCT02824835

Intervention type: PROCEDURE
Intervention: biopsy during colonoscopy
Description: sampling the lesion with forcept biopter

Intervention type: PROCEDURE
Intervention: biopsy during colonoscopy
Description: sampling the lesion with forcept biopter
Study: NCT04156126

Intervention type: OTHER
Intervention: Blood Collection
Description: Blood Collection

Intervention type: OTHER
Intervention: Blood Collection
Description: Blood Collection
Study: NCT04270617

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga program
Description: The intervention will be a 6-week ashtanga yoga program designed by world-renowned yogi Eddie Stern. Eddie Stern is an internationally known Ashtanga yoga teacher, in independent practice not affiliated with NYULH, who has done significant work exploring the physiology and science of yoga. He is not currently engaged in his own research. The yoga protocol for chronic back pain was designed with poses specific to addressing core strength but are gentle enough for patients in pain. The protocol is designed to be directed by a teacher initially but can be done at home and is only 18 minutes in duration.
Study: NCT00209001

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Acupuncture using enhanced Ming Men technique for 20 minutes, twice during 1st week, then once during week 2, 3,and 4.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture therapy
Description: Sham procedure will be insertion of 5 needles for 20 minutes provided twice during first week, then once per week thereafter.
Study: NCT03327818

Intervention type: PROCEDURE
Intervention: hysterectomy

Intervention type: PROCEDURE
Intervention: uterine conservative study
Study: NCT02633969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin Capsules low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin Capsules high dose
Study: NCT05510258

Intervention type: OTHER
Group type: OTHER
Intervention: Physiotherapy
Description: TWO GROUPS CONTROL ND EXPERIMENTAL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: TWO GROUPS CONTROL ND EXPERIMENTAL
Study: NCT02364687

Intervention type: RADIATION
Intervention: Computed tomography late enhancement imaging
Study: NCT05586997

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bonded-Hyrax
Description: The expansion screw of the bonded-hyrax will be activated until the palatal cusps of the permanent maxillary first molars are opposing the buccal cusps of the permanent mandibular first molars

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bonded-Hyrax
Description: The expansion screw of the bonded-hyrax will be activated until the palatal cusps of the permanent maxillary first molars are opposing the buccal cusps of the permanent mandibular first molars

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Bonded Rapid Maxillary Expansion and low-Level Laser therapy
Description: Ten sessions of 0.5 watts for 20 seconds at 4 points along the mid-palatal suture
Study: NCT02038179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Participants who received allopurinol as urate lowering therapy, at a daily dose of 300 mg once daily by mouth for a 4 week duration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Participants who received allopurinol as urate lowering therapy, at a daily dose of 300 mg once daily by mouth for a 4 week duration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants who received placebo tablet (matching Allopurinol 300 mg) daily by mouth for a 4 week duration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants who received placebo tablet (matching Allopurinol 300 mg) daily by mouth for a 4 week duration.
Study: NCT04351165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMP4297
Description: IMP4297 10mg/capsule; IMP4297 20mg/capsule;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMP4297
Description: IMP4297 10mg/capsule; IMP4297 20mg/capsule;
Study: NCT04078711

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Losartan 100Mg Tab
Description: 100Mg Tab, qd, po, 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan 100Mg Tab
Description: 100Mg Tab, qd, po, 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qianyangyuyin 20g Granule
Description: 20g, Granule, bid, po, 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Similar granule manufactured to mimic qianyangyuyin granule, 20g, Granule, bid, po, 6 months
Study: NCT04835727

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Semi-vegetarian diet and increase fiber consumption
Description: All patients in this study will be advised by an experienced nutritionist to intake high fiber diets with a low intake of red meat and processed food.
Study: NCT04189432

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCM-CGH
Description: SCM-CGH will be administrated 3 times with 2-week intervals by IV infusion to subjects at Weeks 0, 2 and 4 (Visits 2, 3 and 4).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administrated 3 times with 2-week intervals by IV infusion to subjects at Weeks 0, 2 and 4 (Visits 2, 3 and 4).
Study: NCT00953888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5069
Description: Single dose of oral solution.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of oral solution.
Study: NCT05046015

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 10% Urea foot lotion
Description: During the course of the study participants cleanse one foot (previously randomized) once daily using the mild cleanser Cetaphil® Restoraderm Body Wash and apply the product Excipial® U10 Lipolotion 10% Urea once daily in the evening by themselves.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 10% Urea foot ointment
Description: During the course of the study participants cleanse one foot (previously randomized) once daily using the mild cleanser Cetaphil® Restoraderm Body Wash and apply the product Excipial® U10 ointment10% Urea once daily in the evening by themselves.
Study: NCT00149396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NV1020
Description: NV1020 dose levels: 3x10\^6, 1x10\^7, 3x10\^7, and 1x10\^8 plaque forming units, administered via hepatic artery infusion, over 10 minutes and repeated every 1-2 weeks for 4-8 weeks
Study: NCT04297605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg
Study: NCT02764502

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pressure Gauge Manometer
Description: Identification of epidural space
Study: NCT03086629

Intervention type: OTHER
Group type: OTHER
Intervention: Patient Concerns Inventory

Intervention type: OTHER
Group type: OTHER
Intervention: No Patient Concerns Inventory
Study: NCT02236312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03069534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RhIL-2
Description: RhIL-2 treatment intervention was consisted of four courses of low-dose rhIL-2 plus standard anti-tuberculosis chemotharapy. rhIL-2 (500,000 U/m)regimen was given subcutaneously (SC) once every other day (q.o.d.) for 30 days and four courses were carried out separately during months 1, 3, 5, and 7.